Targeting arginine metabolism overcomes chemotherapy resistance in aggressive-variant prostate cancers

Summary: Aggressive-variant prostate cancers (AVPCs) respond poorly to anti-androgen therapy but show sensitivity to taxane-platinum chemotherapy, though outcomes remain poor. We conducted a phase 2 trial testing induction cabazitaxel plus carboplatin (CabCarb) followed by olaparib maintenance versu...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Elavarasan Subramani, Patrick G. Pilié, Rebecca Slack-Tidwell, Paul V. Viscuse, Xianghong Kuang, Thirukumaran Kandasamy, Dominik Awad, Jenny J. Han, Licai Huang, Christine B. Peterson, Amado J. Zurita, Sumit K. Subudhi, Paul G. Corn, Rama Soundararajan, Peter Shepherd, Badrajee Piyarathna, Vasanta Putluri, Nagireddy Putluri, Arun Sreekumar, Yuzhuo Wang, Amina Zoubeidi, Iqbal Mahmud, Sara A. Martinez, Lin Tan, Philip L. Lorenzi, Sreyashi Basu, Sonali Jindal, Padmanee Sharma, Christopher J. Logothetis, Timothy C. Thompson, Daniel E. Frigo, Ana M. Aparicio
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Elsevier 2026-06-01
Edice:	iScience
Témata:	Health sciences Medicine Medical specialty Oncology
On-line přístup:	http://www.sciencedirect.com/science/article/pii/S2589004226015592
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!